Publications by authors named "Agnes Olivrie"
Increasing evidence supports a role for small extracellular vesicles (sEV, including exosomes) in Diffuse Large B-cell lymphoma (DLBCL) progression and resistance to treatment. CD20 and PD-L1 are found on DLBCL-derived sEV, but little is known about their patient-level heterogeneity. Moreover, the capacity of PD-L1 sEV to modulate T cells needs to be clarified.
View Article and Find Full Text PDFArticle Synopsis
- - A study of 279 hairy-cell leukemia (HCL) patients revealed a median survival of 27 years and a median relapse-free survival of 11 years after first-line treatment with purine analogs (PNAs), mostly cladribine or pentostatin, followed over 10 years.
- - The incidence of relapse was 39% over 10 years, with second-line therapy achieving a median relapse-free survival of 7 years, regardless of whether the same or another PNA was used.
- - Among the patients, 68 second malignancies were identified, showing an increased risk for solid and hematological cancers; however, the use of PNAs was not linked to a higher risk of these additional cancers
Background: Diffuse large B-cell lymphomas (DLBCLs) are aggressive lymphomas accounting for approximately a third of non-Hodgkin lymphomas. Prohibitin 1 (PHB1) and prohibitin 2 (PHB2) are scaffold proteins that promote mitochondria homeostasis and consequently cell survival, but biological functions of cytoplasmic PHBs remain largely unknown in DLBCL.
Methods: PHB expression was analyzed in 82 DLBCL biopsies and five DLBCL cell lines by immunohistochemistry (IHC) and Western blotting.
Background: Diffuse large B-cell lymphoma (DLBCL) is a fatal malignancy that needs to identify new targets for additional therapeutic options. This study aimed to clarify the clinical and biological significance of endogenous neurotrophin (nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF)) in DLBCL biopsy samples and cell lines.
Methods: We analysed expression of NGF, BDNF, and their receptors (Trk, p75(NTR)) in 51 biopsies and cell lines by immunohistochemistry, immunofluorescence, and western blotting.
Article Synopsis
- A study assessed prognostic factors for identifying Hodgkin lymphoma (HL) patients at risk of treatment resistance or relapse, focusing on CD68 expression and interim PET (iPET) results among 158 patients diagnosed between 1995 and 2011.
- Patients with low CD68 expression (≤25% positive cells) had significantly better five-year overall survival (88.4%) and progression-free survival (74.5%) than those with high expression (>25% positive cells, 63.2% and 40.7%, respectively).
- The study found a correlation between CD68 levels and iPET results, with positive iPET more common in patients with high CD68, suggesting CD68 can help better stratify patient
Background: To determine whether proapoptotic proteins were associated with clinicopathologic heterogeneity and influenced survival in patients with diffuse large B-cell lymphoma (DLBCL), we evaluated patterns of expression of the BCL-2 family member BAD, PP1alpha (the catalytic subunit of PP1 involved in activation of BAD), and apoptosis-inducing factor (AIF).
Patients And Methods: We retrospectively analyzed 46 patients all treated with standard chemotherapy ([CHOP] cyclophosphamide/doxorubicin/vincristine/prednisone-like); of these, 16 received rituximab. Immunohistochemical analyses were performed from biopsy samples of nodal DLBCL that were performed at initial diagnosis.